FDA Grants Priority Review for BridgeBio's Infigratinib in Pediatric Achondroplasia

The U.S. FDA has granted Priority Review to BridgeBio's oral infigratinib for treating pediatric achondroplasia. This status aims to accelerate the availability of a new oral treatment option for children with this rare genetic bone growth disorder, potentially offering an alternative to current daily injectable therapies.